Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers.
Jia H, Deng W, Hao B, Cai M, Guo D, Cai Y, Dai X, Wu Z, He W, Wang J, Wang G, Xia S, Li N, Su W, Dai G.
Jia H, et al. Among authors: xia s.
ACS Med Chem Lett. 2024 Apr 18;15(5):595-601. doi: 10.1021/acsmedchemlett.3c00553. eCollection 2024 May 9.
ACS Med Chem Lett. 2024.
PMID: 38746892